Komori
Governance4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Corporate Governance Report 2024/08/01

The report presents the governance structure, including the Board of Directors and Audit and Supervisory Committee, as a company with an Audit and Supervisory Committee, as well as the skills matrix for directors and executive officers. Changes from the previous report are not specified in the body of the report.

Worth reading
50Recurring
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Number of directors11 (including 4 Outside Directors)
Committee4
指名報酬委員会サステナビリティ委員会リスク管理委員会コンプライアンス委員会
Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
Number of directors11 (including 4 Outside Directors)
Committee指名報酬委員会(社外委員の割合はNot disclosed)、サステナビリティ委員会、リスク管理委員会、コンプライアンス委員会(社外委員の割合はNot disclosed)
Items this document does not state (5)
Number of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Not disclosed

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2024/08/01 | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori